Moreover, the in vivo knockdown of SRC-1 in thyroid cancer reduced the numbers of LYVE-positive lymphatic vessels in mice, indicating the involvement of SRC-1 in lymphangiogenesis. Here, SRC is linked to thyroid gland carcinoma.